Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is positioned for long-term success as its recent FDA approval of Neurolief’s Proliv™Rx system opens up opportunities for growth in both the at-home and in-clinic market segments. With a 12-month price target of $30 per share and a projected 12-month revenue of $60.4M, BrainsWay's valuation appears to be undervalued compared to other medtech companies. However, potential risks to consider include slower market uptake, difficulty in expanding reimbursement and market access, limitations in advancing into other indications, and a potential for long-term dilution.

Bears say

BrainsWay is facing several challenges that may make it difficult for the company to meet its ~$640M total firm value and $15 per share target. These risks include potential slow adoption of their Deep TMS systems, challenges in expanding reimbursement and market access, and potential difficulties in successfully advancing in new indications. Additionally, if BrainsWay faces long-term dilution risk, it could further impact their financials and overall outlook.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.